Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tezebarrier: Tezepelumab in Severe Asthma
NCT07046117Not yet recruiting
- Sponsor
- Medical University of Vienna
- Start
- Oct 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of tezepelumab in asthma (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Change in cell index at 6 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07046117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07046117.